Accolade Stockholders Approve Merger with Transcarent
Deal News | Mar 27, 2025 | Globenewswire
Stockholders of Accolade, a personalized healthcare company listed on NASDAQ under the symbol ACCD, have approved its merger with Transcarent, a company focused on simplifying healthcare access. The approval came during a special meeting, and the merger aims for completion in the second quarter of 2025, pending customary closing conditions and regulatory approvals. Once finalized, Accolade will become privately held, and its shares will no longer be publicly traded. This strategic merger is positioned to enhance the healthcare services offered by both companies, leveraging technology, and care navigation. Advising Transcarent on the merger, Evercore acts as their exclusive financial advisor, supported by legal expertise from Wilson Sonsini Goodrich & Rosati. Accolade is advised by Morgan Stanley & Co LLC as their financial advisor and Cooley LLP on legal matters. The merger is seen as a path to enhancing quality care and streamlining operations, reflecting broader trends in personalized healthcare and digital health innovation, amidst concerns about potential risks, including regulatory hurdles and market volatility.
Sectors
- Healthcare
- Technology
- Mergers and Acquisitions
Geography
- United States – Accolade and Transcarent are U.S.-based companies, and the regulatory approvals referenced are related to U.S. state agencies.
Industry
- Healthcare – Accolade and Transcarent operate within the healthcare sector, focusing on personalized and accessible healthcare services.
- Technology – The merger emphasizes the use of technology, such as generative AI, to enhance healthcare delivery and outcomes.
- Mergers and Acquisitions – The article discusses a merger transaction between Accolade and Transcarent.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Accolade | Target Company | Company | A personalized healthcare company listed on NASDAQ, providing comprehensive healthcare solutions. |
| Transcarent | Bidding Company | Company | A company offering simplified healthcare access, focusing on high-quality, affordable care solutions. |
| Evercore | Financial Advisor | Company | Acting as the exclusive financial advisor to Transcarent for the merger. |
| Wilson Sonsini Goodrich & Rosati | Legal Advisor | Company | Providing legal advice to Transcarent. |
| Morgan Stanley & Co LLC | Financial Advisor | Company | Serving as the exclusive financial advisor to Accolade. |
| Cooley LLP | Legal Advisor | Company | Providing legal counsel to Accolade. |
| U.S. Securities and Exchange Commission (SEC) | Government | Government | Oversight of the merger process, including the submission of Form 8-K. |